These results are encouraging for further development of 211At-AuNP-trastuzumab as an innovative α-radiation nanomedicine for local therapy of HER2-positive cancers due to high tumor retention, internalization, and specific tumor cell binding. Here, ERBB2 is linked to neoplasm.